These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30041583)

  • 1. Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Forshay CM; Streeter SO; Salch SA; Eckel SF
    J Oncol Pharm Pract; 2019 Jul; 25(5):1160-1166. PubMed ID: 30041583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of closed system transfer devices for turnaround time and ease of use.
    Nurgat ZA; Lawrence M; Elhassan TA; Al Nahedh M; Ashour M; Alaboura D; Al-Jazairi AS; Al-Jedai A
    J Oncol Pharm Pract; 2019 Jul; 25(5):1142-1151. PubMed ID: 29958506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Six Commercially Available Closed-System Drug-Transfer Devices Against NIOSH's 2015 Draft Vapor Protocol.
    Halloush S; Reveles IA; Koeller J
    Hosp Pharm; 2020 Dec; 55(6):391-399. PubMed ID: 33245720
    [No Abstract]   [Full Text] [Related]  

  • 4. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs.
    Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M
    PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of three barrier-type closed system transfer devices using the 2015 NIOSH vapor containment performance draft protocol.
    Szkiladz A; Hegner S
    Drugs Ther Perspect; 2022; 38(4):177-184. PubMed ID: 35313703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding.
    Piccardo MT; Forlani A; Izzotti A
    Int J Environ Res Public Health; 2021 Jul; 18(15):. PubMed ID: 34360250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2021; 25(6):515-522. PubMed ID: 34807847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2022; 26(1):72-79. PubMed ID: 35081047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
    Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF
    J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of unintended volume loss of six closed system transfer devices.
    Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W
    J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupational exposures to styrene vapor in a manufacturing plant for fiber-reinforced composite wind turbine blades.
    Hammond D; Garcia A; Feng HA
    Ann Occup Hyg; 2011 Jul; 55(6):591-600. PubMed ID: 21597049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hazardous Drug Enteral Device: A Closed System Device for Crushing and Dispersing Hazardous Drug Tablets for Enteral Administration.
    López CV; Quito GLR
    Int J Pharm Compd; 2022; 26(5):358-362. PubMed ID: 36053761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syringe plunger contamination by hazardous drugs: a comparative study.
    Smith ST; Szlaczky MC
    J Oncol Pharm Pract; 2014 Oct; 20(5):381-5. PubMed ID: 24598373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.